Viokase
Is a New Crohn's Disease Treatment on the Horizon? »
"Oct. 17, 2012 -- A drug used to treat psoriasis may provide a much-needed option for people with bad cases of Crohn's disease.
In the new study, some people with moderate to severe Crohn's given Stelara (ustekinumab) began to see imp"...
Read the Is a New Crohn's Disease Treatment on the Horizon? article »
Viokase
CLINICAL PHARMACOLOGY
The natural digestive enzymes in VIOKASE® (pancrelipase tablets, powder) hydrolyze fats into fatty acids and glycerol, split protein into amino acids, and convert carbohydrates to dextrins and short chain sugars.
Under conditions of the USP test method (in vitro) VIOKASE® (pancrelipase tablets, powder) has the following total digestive capacity:
| VIOKASE® 8 Tablet |
VIOKASE® 16 Tablet |
VIOKASE® Powder Each 0.7 g (1/4 Teaspoonful) |
|
| Dietary fat, grams | 28 | 56 | 59 |
| Dietary protein, grams | 30 | 60 | 70 |
| Dietary starch, grams | 30 | 60 | 70 |
VIOKASE® (pancrelipase tablets, powder) 8 Tablets are 468 mg immediate release tablets and are not enteric-coated. VIOKASE® (pancrelipase tablets, powder) 16 Tablets are 935 mg immediate release tablets and are not enteric-coated.
The digestive capacity of a pancreatic enzyme concentrate depends on the amount that passes through the stomach unchanged and is available at the site of action in the small intestine.
Last reviewed on RxList: 12/9/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Viokase Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
GI Disorders
Get the latest treatment options.
Updated & New
